Price Action To Observe: Could Agios Pharmaceuticals Inc Gain Strenght? The Stock Reaches Yearly Low

Price Action To Observe: Could Agios Pharmaceuticals Inc Gain Strenght? The Stock Reaches Yearly Low

The stock of Agios Pharmaceuticals Inc (NASDAQ:AGIO) is a huge mover today! About 501,451 shares traded hands. Agios Pharmaceuticals Inc (NASDAQ:AGIO) has risen 36.91% since April 14, 2016 and is uptrending. It has outperformed by 32.22% the S&P500.
The move comes after 6 months negative chart setup for the $2.74 billion company. It was reported on Nov, 16 by Barchart.com. We have $58.55 PT which if reached, will make NASDAQ:AGIO worth $164.40M less.

Agios Pharmaceuticals Inc (NASDAQ:AGIO) Ratings Coverage

Out of 12 analysts covering Agios Pharmaceuticals (NASDAQ:AGIO), 7 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 58% are positive. Agios Pharmaceuticals has been the topic of 20 analyst reports since July 23, 2015 according to StockzIntelligence Inc. The rating was initiated by Needham with “Buy” on Monday, October 24. Credit Suisse maintained Agios Pharmaceuticals Inc (NASDAQ:AGIO) on Wednesday, May 18 with “Outperform” rating. The firm earned “Neutral” rating on Monday, November 9 by Roth Capital. Canaccord Genuity maintained the stock with “Hold” rating in Friday, August 7 report. Suntrust Robinson maintained the shares of AGIO in a report on Wednesday, May 18 with “Buy” rating. The stock of Agios Pharmaceuticals Inc (NASDAQ:AGIO) has “Hold” rating given on Wednesday, August 5 by Roth Capital. Janney Capital initiated Agios Pharmaceuticals Inc (NASDAQ:AGIO) on Wednesday, March 2 with “Neutral” rating. The firm has “Buy” rating by SunTrust given on Wednesday, March 30. The rating was initiated by BTIG Research on Friday, August 19 with “Neutral”. The firm has “Overweight” rating given on Monday, June 13 by JP Morgan.

According to Zacks Investment Research, “Agios Pharmaceuticals, Inc. is a biopharmaceutical company. It discovers and develops therapeutics in the field of cancer metabolism and inborn errors of metabolism. The Company’s products include AG-221, AG-120, enzyme glutaminase and AG-348. Agios Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.”

Insitutional Activity: The institutional sentiment increased to 1.39 in 2016 Q2. Its up 0.03, from 1.36 in 2016Q1. The ratio improved, as 22 funds sold all Agios Pharmaceuticals Inc shares owned while 37 reduced positions. 18 funds bought stakes while 64 increased positions. They now own 35.06 million shares or 11.59% more from 31.42 million shares in 2016Q1.
Cormorant Asset Limited Liability Co owns 50,000 shares or 0.3% of their US portfolio. California State Teachers Retirement System, a California-based fund reported 59,941 shares. The Switzerland-based Gam Holding Ag has invested 0.03% in Agios Pharmaceuticals Inc (NASDAQ:AGIO). Barclays Plc has 0% invested in the company for 189 shares. Envestnet Asset Inc has 2,542 shares for 0% of their US portfolio. Jennison Lc holds 169,974 shares or 0.01% of its portfolio. Guardian Company holds 668,100 shares or 0.22% of its portfolio. Fiera Corp accumulated 231,687 shares or 0.05% of the stock. Manufacturers Life Insurance Company The has invested 0% of its portfolio in Agios Pharmaceuticals Inc (NASDAQ:AGIO). Td Asset Management owns 13,200 shares or 0% of their US portfolio. Mutual Of America Capital Management Ltd Liability Company last reported 0.02% of its portfolio in the stock. Teachers Retirement Of The State Of Kentucky accumulated 41,518 shares or 0.02% of the stock. Royal Bancorp Of Canada holds 0% or 4,364 shares in its portfolio. The New York-based Millennium Management Limited Liability Com has invested 0.01% in Agios Pharmaceuticals Inc (NASDAQ:AGIO). Seven Eight Ltd Co has 0% invested in the company for 22 shares.

Insider Transactions: Since May 25, 2016, the stock had 0 insider buys, and 9 selling transactions for $3.20 million net activity. 5,000 shares with value of $250,000 were sold by Biller Scott on Tuesday, September 20. $93,424 worth of Agios Pharmaceuticals Inc (NASDAQ:AGIO) was sold by Cantley Lewis Clayton Jr..

More notable recent Agios Pharmaceuticals Inc (NASDAQ:AGIO) news were published by: Fool.com which released: “Why Agios Pharmaceuticals Inc Stock Skyrocketed Today” on September 07, 2016, also Fool.com with their article: “Why Agios Pharmaceuticals Inc. Presented Lower Today” published on June 09, 2016, Fool.com published: “3 Big Reasons Agios Pharmaceuticals, Inc. Has Plunged 38% in 2016” on July 03, 2016. More interesting news about Agios Pharmaceuticals Inc (NASDAQ:AGIO) were released by: Fool.com and their article: “The Silly Reason Why Agios Pharmaceuticals Inc. Was Clobbered in January” published on February 06, 2016 as well as Fool.com‘s news article titled: “A Short Squeeze and the Rumor Mill Stir Up Agios Pharmaceuticals, Inc. in April” with publication date: May 06, 2016.

AGIO Company Profile

Agios Pharmaceuticals, Inc., incorporated on August 7, 2007, is a biopharmaceutical company. The Firm is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs), which are a subset of orphan genetic metabolic diseases. The Company’s cancer product candidates are AG-221 and AG-120, which targets mutated isocitrate dehydrogenase 2 and 1, or IDH2 and IDH1, respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its RGD programs, AG-348, which targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment